What other benefits does Wegovy offer beyond weight loss?

Does Wegovy actually reduce the risk of heart attack and stroke?

Yes, and this is not a secondary finding buried in a footnote. The MHRA has granted Wegovy a specific UK licence for reducing the risk of major cardiovascular events, including heart attack and stroke, in adults who have established cardiovascular disease and a BMI of at least 27. This approval is separate from its weight-management indication and rests on its own body of evidence.

The SELECT trial, a large cardiovascular outcomes study, found that semaglutide 2.4 mg reduced the rate of major adverse cardiovascular events by around 20% compared with placebo in participants who already had cardiovascular disease. Notably, many of those participants were not people with type 2 diabetes, which had previously been the primary cardiovascular context for GLP-1 medicines. The reduction in events was observed on top of standard cardiovascular treatments these participants were already receiving.

What drives this effect is still being studied. Weight loss contributes, but the magnitude of the cardiovascular benefit appears greater than weight reduction alone would predict, suggesting that GLP-1 receptor activity may have direct effects on inflammation and arterial function. For anyone with a relevant cardiac history, this is worth raising with a prescriber. You can read more about how semaglutide works across these pathways on our semaglutide overview.

What is the liver disease approval, and who does it affect?

On 3 July 2026 the MHRA conditionally approved Wegovy (semaglutide) for the treatment of MASH (metabolic dysfunction-associated steatohepatitis) in adults with moderate-to-advanced liver fibrosis. This makes it the first medicine in the UK to hold a licence for this specific condition, which affects a significant proportion of people living with obesity and type 2 diabetes.

MASH is a progressive form of fatty liver disease in which fat accumulation triggers inflammation and scarring (fibrosis). Left untreated, it can advance to cirrhosis or liver failure. Until this approval, there was no licensed pharmacological treatment; management relied on lifestyle changes and management of underlying conditions. The MASH approval is a conditional one, meaning post-approval data collection continues, and prescribing for this indication falls within specialist settings. It is distinct from prescribing Wegovy for weight management, and a prescriber will assess whether this indication applies to a patient's specific liver disease stage and history.

For context on the broader UK approval landscape for Wegovy, the Wegovy page on our site covers the full picture of what is currently licensed here.

Are there other measurable health improvements reported during treatment?

Several. People using Wegovy in clinical trials consistently showed improvements in a cluster of cardiometabolic markers beyond the primary weight endpoint. Blood pressure fell, on average, by clinically meaningful amounts. LDL cholesterol and triglyceride levels improved. Fasting blood glucose and HbA1c figures moved favourably even in participants who did not have a diabetes diagnosis at baseline, suggesting beneficial effects on insulin sensitivity.

Sleep apnoea is another area drawing attention. Emerging evidence points to reductions in the severity of obstructive sleep apnoea during semaglutide treatment, likely connected to reduced fat around the neck and upper airway, though research in this area continues. Quality of life measures (physical mobility, energy, and self-reported wellbeing) also improved in trial populations, reflecting the compound effect of weight change alongside these metabolic shifts.

None of these should be read as a guaranteed outcome for any individual. Trials report averages across large populations; your own response depends on your starting health profile, how long you stay on treatment, and the lifestyle changes you make alongside it. The health benefits of Wegovy page goes deeper on the evidence behind these individual markers.

It is also worth knowing that in January 2026 the MHRA issued an update on GLP-1 medicines and the risk of acute pancreatitis, flagging it as an infrequent but serious side effect to be aware of. If you want to understand the full side-effect profile alongside these benefits, our Wegovy side effects page covers what the evidence says on both counts.

How does the 7.2 mg dose change the benefit picture?

In April 2026 the MHRA approved a dedicated single-dose 7.2 mg Wegovy pen, the highest semaglutide dose licensed anywhere for weight management. Trials at this dose reported average weight loss of around 20.7% over 72 weeks, narrowing the gap with tirzepatide's results in the SURMOUNT programme. Greater weight reduction generally correlates with more pronounced improvements in blood pressure, glucose regulation, and other cardiometabolic markers, so the higher dose may amplify some of the benefits described above.

Whether 7.2 mg is appropriate for a given patient is a clinical question. Titration still begins at 0.25 mg and proceeds through a slow schedule set by the prescriber; the highest dose is never the starting point. Availability of specific dose formats is confirmed at consultation rather than assumed. If you are weighing up the two currently available injectable weight-loss medicines and want to understand what the evidence shows about their respective benefit profiles, our semaglutide benefits page and the broader semaglutide benefits overview both cover this in detail. A note on timing: if you are thinking about starting treatment, orders placed before 12pm on a working day are dispatched the same day once clinically approved, which can matter if you are planning around a busy week. Check your eligibility through a free consultation with our prescribers to see whether Wegovy is suitable for your situation.